Astrotech (ASTC) - 2025 Q3 - Quarterly Results

Revenue and Sales Performance - Fiscal Year 2025 Q3 revenue reached $534 thousand, a significant increase from$50 thousand in Q3 of Fiscal Year 2024, driven by TRACER 1000™ shipments, a government grant, and recurring sales[4] - The gross profit for Q3 of Fiscal Year 2025 was $237 thousand, a notable increase from$8 thousand in Q3 of Fiscal Year 2024[10] Expenses and Losses - The net loss for Q3 of Fiscal Year 2025 was $3.633 million, compared to a net loss of$3.154 million in Q3 of Fiscal Year 2024[10] - Operating expenses for Q3 of Fiscal Year 2025 were $4.104 million, compared to$3.541 million in Q3 of Fiscal Year 2024, reflecting increased investment in R&D and marketing[10] Cash and Equity - Cash, cash equivalents, and liquid investments totaled $20.9 million as of March 31, 2025, down from$31.9 million at June 30, 2024[4] - Total stockholders' equity decreased to $24.752 million as of March 31, 2025, down from$34.807 million at June 30, 2024[12] Product Development and Launches - The Company launched four product lines, including TRACER NTD, Pro-Control, and EN-SCAN, aimed at expanding sales opportunities in various markets[2] - A research and development contract worth $429 thousand was awarded to the 1st Detect subsidiary by the Department of Homeland Security for the TRACER 1000 project[4] - The Company created a new wholly owned subsidiary, EN-SCAN, Inc., to manufacture and sell instruments for environmental testing applications[4] - The TRACER 1000 NTD has been configured to screen for synthetic opiates and novel psychoactive substances, enhancing its capabilities in drug detection[4]